/ /

  • linkedin
  • Increase Font
  • Sharebar

    IRIS Registry shaping up to be extensive data source

    Tool serves as resource with applications, such as quality measurement, reporting, research

    IRIS Registry shaping up
    to be extensive data source


    The Intelligent Research in Sight (IRIS) Registry—a comprehensive eye disease registry developed by the American Academy of Ophthalmology (AAO)—has far surpassed early estimates for physician participation, according to William L. Rich III, MD, FACS.

    The registry has become a comprehensive data source with applications for clinical improvement, data analysis, and scientific research, said Dr. Rich, medical director of health policy for the AAO and chairman of the IRIS Executive Committee.

    IRIS was approved by the academy board in late 2012 and launched in April 2014. At the time, Dr. Rich had estimated that by January 2018 the registry would include 2,200 physicians and 8 million patients.

    His predictive skills were off—as by October 2017 the registry had contracted with 16,503 physicians from 5,119 practices. Of these, 13,046 physicians from 5,119 practices were integrated into IRIS through electronic health records. The number of patient visits was 166.16 million, representing 41.22 million patients.

    “My subsequent estimation of 48 million patients by 2018 is going to hold up, and what that means is that we’re the world’s largest registry, and we’re a much better data source than even the Medicare registry,” Dr. Rich said.

    Also heartening is that the IRIS Registry includes about 70% of the practicing ophthalmologists in the United States. Most of those not participating work for the Department of Defense or Veterans Administration or are employed by academic medical centers.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results